Jim Cramer’s Top 12 Must-Watch Stocks

9. Moderna Inc. (NASDAQ:MRNA)

Number of Hedge Fund Investors: 39

Jim Cramer expressed disappointment in Moderna Inc. (NASDAQ:MRNA), noting that despite having ample funding, the company has not delivered expected results. He believes they urgently need to develop a personalized vaccine to regain credibility and momentum.

“MRNA has been a big disappointment. They had all that money; I would have thought they could come up with something. They need to come up with a personalized vaccine right now.”

Moderna, Inc. (NASDAQ:MRNA) is backed by its innovative mRNA technology platform, strong financial results, and significant growth potential in various therapeutic areas. While known for its COVID-19 vaccines, Moderna, Inc. (NASDAQ:MRNA)’s platform can also develop treatments for infectious diseases, cancer, and rare genetic disorders.

In its recent Q2 2024 earnings report, Moderna, Inc. (NASDAQ:MRNA) reported revenues of $3.6 billion, primarily from ongoing COVID-19 vaccine sales and contributions from its diverse product pipeline. This resulted in a net income of $1.2 billion, showcasing strong profitability. Moderna, Inc. (NASDAQ:MRNA) is expanding into new markets, including treatments for flu and respiratory viruses, and its strategic partnerships are designed to speed up the development of these products.

With considerable investments in research and development, Moderna, Inc. (NASDAQ:MRNA) is well-positioned to take advantage of emerging healthcare trends and meet unmet medical needs. The rising interest in personalized medicine and its ability to quickly develop and scale new vaccines and treatments enhance its competitive edge. Recent positive results from trials for its Moderna, Inc. (NASDAQ:MRNA) based flu vaccine and new collaboration agreements highlight Moderna’s commitment to leveraging its technology and expanding market opportunities, suggesting a bright future for the company.